As of 9:45am ET
| +0.0285 / +7.92%|
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.
|Thomas Kenwood Equels||Executive Vice Chairman, President & CEO|
|Wayne S. Springate||Senior Vice President-Operations|
|Adam Pascale||Chief Financial Officer|
|David R. Strayer||Chief Scientific & Medical Officer|
|Peter W. Rodino||Secretary & General Counsel|